Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 22:32 UTC |
Lieber Jonathan IDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-380584 · ownership.xml · nonDerivative · entry 1 Lieber Jonathan I · CIK 0001350090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,002 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:50 UTC |
PIERCE FREDERICK IIChief Executive Officer
|
GrantCommon Stock | 33,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001229055-26-000002 · ownership.xml · nonDerivative · entry 1 PIERCE FREDERICK II · CIK 0001229055 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,844 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:49 UTC |
Marschel Peter KlausChief Business Officer
|
GrantCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0002079859-26-000002 · ownership.xml · nonDerivative · entry 1 Marschel Peter Klaus · CIK 0002079859 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:48 UTC |
Rosenblum Mark JChief Financial Officer
|
GrantCommon Stock | 9,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001329154-26-000003 · ownership.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,363 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:46 UTC |
Hibner Barbara LouiseChief Scientific Officer
|
GrantCommon Stock | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0002079512-26-000002 · ownership.xml · nonDerivative · entry 1 Hibner Barbara Louise · CIK 0002079512 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,216 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:45 UTC |
HANISH ARNOLD CDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001233253-26-000006 · ownership.xml · nonDerivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,418 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:42 UTC |
Lammers PaulDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001457289-26-000003 · ownership.xml · nonDerivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,001 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:41 UTC |
Burleson TessDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001769749-26-000003 · ownership.xml · nonDerivative · entry 1 Burleson Tess · CIK 0001769749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,002 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:40 UTC |
McVicar William K.Director
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001634368-26-000003 · ownership.xml · nonDerivative · entry 1 McVicar William K. · CIK 0001634368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,002 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:39 UTC |
Gauthier Patricia G.Director
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002148287-26-000002 · ownership.xml · nonDerivative · entry 1 Gauthier Patricia G. · CIK 0002148287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027. Read SEC document |
| December 30, 2025 Filed Jan 2, 2026 22:13 UTC |
HANISH ARNOLD CDirector
|
SaleCommon Stock | 12 | $0.64 | $7.68 |
DisclosureSEC source: 0001615219-26-000004 · wk-form4_1767392031.xml · nonDerivative · entry 2 HANISH ARNOLD C · CIK 0001233253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 30, 2025 Filed Jan 2, 2026 22:13 UTC |
HANISH ARNOLD CDirector
|
SaleCommon Stock | 15 | $0.64 | $9.60 |
DisclosureSEC source: 0001615219-26-000004 · wk-form4_1767392031.xml · nonDerivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Arnold C. Hanish Trust Disclosed balance after: 5,000 Read SEC document |
| November 20, 2025 Filed Nov 20, 2025 16:42 UTC |
Rosenblum Mark JExec VP Finance, CFO
|
PurchaseCommon Stock | 20,000 | $0.80 | $16,000.00 |
DisclosureSEC source: 0001615219-25-000177 · wk-form4_1763674926.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,177 F1 · balance_after: Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025. F2 · balance_after: Includes 20 shares of unvested restricted stock granted on January 3, 2023. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:08 UTC |
HANISH ARNOLD CDirector
|
PurchaseCommon Stock | 5,000 | $0.75 | $3,740.50 |
DisclosureSEC source: 0001615219-25-000193 · wk-form4_1764022090.xml · nonDerivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Arnold C. Hanish Trust Disclosed balance after: 5,015 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7437 to $0.75, inclusive. The reporting person undertakes to provide to Salarius Pharmaceuticals, Inc., any security holder of Salarius Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 20:50 UTC |
Arthur David J.Director · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001615219-24-000034 · wk-form4_1712955014.xml · derivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-04-11 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:16 UTC |
Lammers PaulDirector
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000007 · wk-form4_1708636513.xml · derivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-02-19 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:21 UTC |
Lieber Jonathan IDirector
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000009 · wk-form4_1708636836.xml · derivative · entry 1 Lieber Jonathan I · CIK 0001350090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-02-19 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:09 UTC |
HANISH ARNOLD CDirector
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000003 · wk-form4_1708636159.xml · derivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-02-19 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:37 UTC |
Rosenblum Mark JExec VP Finance, CFO
|
GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000015 · wk-form4_1708637819.xml · derivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-02-19 F1 · derivative.exercise_date: 25% of the options are vested on February 20, 2025, and 1/36 of the remaining options vest on each monthly anniversary thereafter for 36 months. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:29 UTC |
McVicar William K.Director
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000013 · wk-form4_1708637336.xml · derivative · entry 1 McVicar William K. · CIK 0001634368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-02-19 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:25 UTC |
McCreedy Bruce J Jr.Director
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000011 · wk-form4_1708637069.xml · derivative · entry 1 McCreedy Bruce J Jr. · CIK 0001769750 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-02-19 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:13 UTC |
Burleson TessDirector
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000005 · wk-form4_1708636372.xml · derivative · entry 1 Burleson Tess · CIK 0001769749 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2034-02-19 Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:06 UTC |
Rosenblum Mark JExec VP Finance, CFO
|
GrantCommon Stock | 6,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000025 · wf-form4_167649515529108.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,851 F1 · shares: Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:04 UTC |
Arthur David J.Director · Chief Executive Officer
|
GrantCommon Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000023 · wf-form4_167649503732734.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,019 F1 · shares: Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:03 UTC |
Lammers PaulDirector
|
GrantCommon Stock | 1,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000010 · wf-form4_167295975197703.xml · nonDerivative · entry 1 Lammers Paul · CIK 0001457289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,718 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:12 UTC |
Lieber Jonathan IDirector
|
GrantCommon Stock | 1,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000015 · wf-form4_167296030411994.xml · nonDerivative · entry 1 Lieber Jonathan I · CIK 0001350090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,940 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:06 UTC |
HANISH ARNOLD CDirector
|
GrantCommon Stock | 1,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000011 · wf-form4_167295996189260.xml · nonDerivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,440 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:35 UTC |
Rosenblum Mark JExec VP Finance, CFO
|
GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000004 · wf-form4_167295812977872.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,419 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 25% of the shares of restricted stock will vest on January 2, 2024, and 1/36 of the remaining shares of restricted stock will vest on monthly anniversary thereafter. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:47 UTC |
Burleson TessDirector
|
GrantCommon Stock | 1,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000008 · wf-form4_167295879982131.xml · nonDerivative · entry 1 Burleson Tess · CIK 0001769749 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,722 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:08 UTC |
McCreedy Bruce J Jr.Director
|
GrantCommon Stock | 1,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000013 · wf-form4_167296009433418.xml · nonDerivative · entry 1 McCreedy Bruce J Jr. · CIK 0001769750 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,788 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:44 UTC |
McVicar William K.Director
|
GrantCommon Stock | 1,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000006 · wf-form4_167295864858566.xml · nonDerivative · entry 1 McVicar William K. · CIK 0001634368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,788 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:33 UTC |
Arthur David J.Director · Chief Executive Officer
|
GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000002 · wf-form4_167295795521891.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,719 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 25% of the shares of restricted stock will vest on January 2, 2024, and 1/36 of the remaining shares of restricted stock will vest on monthly anniversary thereafter. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 16:33 UTC |
Rosenblum Mark JExec VP Finance, CFO
|
GrantCommon Stock | 7,314 | $1.73 | $12,682.48 |
DisclosureSEC source: 0001615219-22-000141 · wf-form4_166785680873414.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,633 F1 · kind: These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c). Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:34 UTC |
Arthur David J.Director · Chief Executive Officer
|
GrantCommon Stock | 10,000 | $1.73 | $17,340.00 |
DisclosureSEC source: 0001615219-22-000142 · wf-form4_166785687791752.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,674 F1 · kind: These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 17:40 UTC Amendment |
Rosenblum Mark JExec VP Finance, CFO
|
GrantCommon Stock | 7,314 | $1.73 | $12,682.48 |
DisclosureSEC source: 0001615219-22-000143 · wf-form4a_166794723949586.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,245 F1 · kind: These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c) Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 22:42 UTC Amendment |
Arthur David J.Director · Chief Executive Officer
|
GrantCommon Stock | 10,000 | $1.73 | $17,340.00 |
DisclosureSEC source: 0001615219-22-000144 · wf-form4a_166794733755240.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,026 F1 · kind: These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c) Read SEC document |
| November 03, 2022 Filed Dec 12, 2022 18:29 UTC Amendment |
Rosenblum Mark JExec VP Finance, CFO
|
GrantCommon Stock | 1,488 | $1.73 | $2,580.19 |
DisclosureSEC source: 0001615219-22-000153 · wf-form4a_167088775808803.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,419 F1 · shares: The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 7,314 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 1,488 shares of common stock. Read SEC document |
| November 03, 2022 Filed Dec 12, 2022 23:34 UTC Amendment |
Arthur David J.Director · Chief Executive Officer
|
GrantCommon Stock | 2,693 | $1.73 | $4,669.66 |
DisclosureSEC source: 0001615219-22-000155 · wf-form4a_167088805437684.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,719 F1 · shares: The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 10,000 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 2,693 shares of common stock. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 15:12 UTC |
Lieber Jonathan IDirector
|
PurchaseCommon Stock | 37,500 | $0.19 | $7,016.25 |
DisclosureSEC source: 0001615219-22-000099 · wf-form4_165471551887755.xml · nonDerivative · entry 1 Lieber Jonathan I · CIK 0001350090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 19:14 UTC |
Burleson TessDirector
|
PurchaseCommon Stock | 27,700 | $0.18 | $4,986.00 |
DisclosureSEC source: 0001615219-22-000101 · wf-form4_165471565849028.xml · nonDerivative · entry 1 Burleson Tess · CIK 0001769749 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,050 Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 20:33 UTC |
McVicar William K.Director
|
PurchaseCommon Stock | 26,553 | $0.19 | $4,999.93 |
DisclosureSEC source: 0001615219-22-000097 · wf-form4_165463398025988.xml · nonDerivative · entry 1 McVicar William K. · CIK 0001634368 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · McVicar Family Trust Disclosed balance after: 26,553 Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 00:33 UTC |
HANISH ARNOLD CDirector
|
PurchaseCommon Stock | 28,000 | $0.18 | $5,152.00 |
DisclosureSEC source: 0001615219-22-000095 · wf-form4_165456196752108.xml · nonDerivative · entry 1 HANISH ARNOLD C · CIK 0001233253 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Arnold C. Hanish Trust Disclosed balance after: 46,350 Read SEC document |
| May 31, 2022 Filed May 31, 2022 17:13 UTC |
Rosenblum Mark JExec VP Finance, CFO
|
PurchaseCommon Stock | 28,000 | $0.18 | $5,040.00 |
DisclosureSEC source: 0001615219-22-000085 · wf-form4_165403159108429.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,319 Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC |
Arthur David J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 10,800 | $0.18 | $1,990.44 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 5 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 303,574 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC |
Arthur David J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 10,392 | $0.18 | $1,869.52 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 4 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 292,774 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC |
Arthur David J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 708 | $0.18 | $127.44 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 3 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 282,382 F1 · shares: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC |
Arthur David J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 18,600 | $0.18 | $3,385.20 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 2 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,674 Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:17 UTC |
Arthur David J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 3,400 | $0.18 | $612.00 |
DisclosureSEC source: 0001615219-22-000087 · wf-form4_165403182105530.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,074 Read SEC document |
| May 03, 2022 Filed May 5, 2022 16:03 UTC |
Rosenblum Mark JExec VP Finance, CFO
|
GrantCommon Stock | 10,000 | $0.19 | $1,863.00 |
DisclosureSEC source: 0001615219-22-000067 · wf-form4_165178098962212.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,319 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:06 UTC |
Arthur David J.Director · Chief Executive Officer
|
GrantCommon Stock | 10,000 | $0.19 | $1,863.00 |
DisclosureSEC source: 0001615219-22-000069 · wf-form4_165178116032585.xml · nonDerivative · entry 1 Arthur David J. · CIK 0001769331 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,674 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.